Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT02440763
Recruiting Observational

The EUROSCA Natural History Study

NCT02440763 · tracked via the Priya Life Science Italy tracker
Sponsor
Ataxia Study Group
Phase
Observational
Started
2005-07
Last updated
2017-06-29

Condition(s) studied

Spinocerebellar Ataxia

Study summary

The key goals of EUROSCA-NHS is to determine and compare the rate of disease progression in SCA1, SCA2, SCA3 and SCA6 including determination of the order and occurrence of non-ataxia symptoms, assessment of activities of daily living (ADL) and quality of life (QoL), and identification of predictors of disease progression and survival.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion criteria: * Progressive, otherwise unexplained ataxia * Positive genetic testing for SCA1, SCA2, SCA3, and SCA6 * Written informed consent by the patient or his legal agent Exclusion criteria: None.

Primary outcome measure(s)

  • Scale for the assessment and rating of ataxia (SARA) — Patients are first seen at a baseline visit, followed by annual visits for 3 years scheduled ± 3 months around the specified time point. After the initial 3 year observation period, visits are done at irregular intervals each time they went to hospital.
    Progression of ataxia is measured using a newly developed and validated ataxia scale, SARA. SARA was evaluated in two large validation trials performed by the EUROSCA clinical group and was found to be easy to use, reliable, and valid.

Trial sites (16)

FacilityCityRegionStatus
Department of Neurology, Medical University, Innsbruck Innsbruck Austria Active Not Recruiting
Université Libre de Bruxelles (ULB), Neurology Service - ULB Hôpital Erasme, ULB Laboratory of Experimental Neurology Brussels Belgium Active Not Recruiting
Hôpital de la Pitié-Salpêtrière, Département de Génétique Paris France Active Not Recruiting
Department of Neurology, St. Josef Hospital, University Hospital of Bochum Bochum Germany Active Not Recruiting
Department of Neurology, University of Bonn Bonn Germany Recruiting
Department of Neurology, University Clinic Essen, University of Duisburg-Essen Essen Germany Active Not Recruiting
Department of Neurology, University of Frankfurt Frankfurt Germany Active Not Recruiting
Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research, University of Tübingen Tübingen Germany Active Not Recruiting
Department of Medical Genetics, University of Pecs Pécs Hungary Active Not Recruiting
Department of Neurology, Zala County Hospital Zalaegerszeg Hungary Active Not Recruiting
Fondazione-IRCCS Istituto Neurologico Carlo Besta Milan Italy Active Not Recruiting
Department of Neuroscience, Federico II University Naples Naples Italy Active Not Recruiting
Radboud University Medical Center, Department of Neurology, Donders Institute for Brain, Cognition, and Behaviour Nijmegen Netherlands Active Not Recruiting
Institute of Psychiatry and Neurology Warsaw Poland Active Not Recruiting
University Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria Santander Spain Active Not Recruiting
Institute of Neurology London United Kingdom Active Not Recruiting

More Ataxia Study Group trials in Italy

Sporadic Degenerative Ataxia With Adult Onset: Natural History Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02440763 on ClinicalTrials.gov ↗ ← All trials in Italy